12:00pm VBC104: A First-in-class CD79b/CD20 Targeted Bi-specific Antibody Drug Conjugate (ADC) with Superior Efficacy vs 1st line CD79b ADC in DLBCL, RT, FL, MCL, MZL and Beyond
Time: 12:00 pm
day: Bispecific ADC Seminar Day
Details:
- The anti-CD79b ADC, Polatuzumab Vedotin (PV), has demonstrated significant clinical benefits in B cell lymphoma and is approved for the first-line therapy. However, there remains a strong unmet medical need for PV-resistant patients and those with Richter's syndrome
- VBC104 is a first-in-class bi-specific antibody-drug conjugate (ADC) targeting both CD79b and CD20. It has the potential to overcome tumor heterogeneity and shows consistent efficacy on tumor cells with different CD79b/CD20 expression profiles
- In vitro and in vivo data demonstrate that VBC104 exhibits superior efficacy compared to PV in both PV sensitive and resistant models, it also exhibits excellent tumor inhibition in PDX model of Richter's syndrome
